Neuroone Medical Technologies CORP

NeuroOne Medical Technologies Corporation has filed a prospectus supplement to sell up to $13.4 million of common stock through an existing at-the-market program.

NeuroOne Medical Technologies Corporation announced fiscal Q2 2026 results, showcasing a 72% year-over-year product revenue increase to $2.4 million and significant clinical progress with its OneRF Trigeminal Nerve Ablation System.

NeuroOne Medical Technologies Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the deficiency matter.

NeuroOne Medical Technologies Corporation announced the retirement of its Chief Financial Officer, Ronald McClurg, effective June 30, 2026, with COO Christopher Volker set to assume the CFO role.

NeuroOne Medical Technologies Corporation is implementing a 1-for-6 reverse stock split, effective April 15, 2026, to adjust its issued and outstanding shares of common stock.

NeuroOne Medical Technologies Corporation held its Annual Meeting on April 3, 2026, where stockholders approved amendments to the equity incentive plan and authorized a reverse stock split.

NeuroOne Medical Technologies Corporation filed an amended 10-Q to correct revenue recognition errors that overstated product revenue and gross profit by $529,000 and $296,000, respectively.

NeuroOne Medical Technologies reported increased product revenue in Q1 2026, though net loss widened due to license revenue recognition in the prior year.

NeuroOne Medical Technologies Corporation reported a net loss of $1.44 million in Q1 2026, a significant decline from the prior year's profit, alongside ongoing Nasdaq compliance issues and substantial doubt about its ability to continue as a going concern.

NeuroOne Medical Technologies reports significant revenue growth and reduced net losses, fueled by its Zimmer partnership and recent capital raise.

NeuroOne Medical Technologies Corporation reports increased product revenue and gross profit for the quarter ended March 31, 2025, driven by OneRF product sales, while still facing net losses and reliance on additional financing.

NeuroOne Medical Technologies reports a significant increase in revenue for the quarter ended December 31, 2024, driven by a licensing agreement with Zimmer, but acknowledges substantial doubt about its ability to continue as a going concern.

NeuroOne Medical Technologies Corporation filed an amendment to its annual report to provide detailed information on executive compensation, corporate governance, and related party transactions for the fiscal year ended September 30, 2025.

NeuroOne Medical Technologies Corporation announced significant product and collaboration revenue growth, leading to a substantial reduction in net loss for the fiscal year ended September 30, 2025, despite ongoing concerns about its ability to continue as a going concern.

NeuroOne Medical Technologies Corporation's 10-K filing details its financial performance for fiscal year 2024, ongoing product development, and strategic initiatives in the neuromodulation space.

Mark Christianson, Market Development Director at NeuroOne Medical Technologies Corp., reported a transaction involving 10,000 shares of common stock.

NeuroOne Medical Technologies Corp reports director Jason Richard Mills acquired restricted stock units and stock options.

NeuroOne Medical Technologies Corp. reports a Form 4 filing detailing stock grants and options awarded to Director Jeffrey S. Mathiesen.

NeuroOne Medical Technologies Corp. reports a Form 4 filing detailing stock transactions by Director Paul Buckman, including the acquisition of restricted stock units and stock options.

NeuroOne Medical Technologies Corp. reports a Form 4 filing detailing stock transactions by Director Edward Andrle.

NEUROONE Medical Technologies' Business Development Director, Mark Christianson, reported the sale of common stock and shares withheld for tax purposes.

NeuroOne Medical Technologies issues a second supplement to its proxy statement to correct the description of the quorum requirements for its upcoming 2025 Annual Meeting of Stockholders.

NeuroOne Medical Technologies amends its 2025 Equity Incentive Plan to remove the evergreen feature following stockholder feedback, seeking approval at the upcoming annual meeting.

NeuroOne Medical Technologies is asking shareholders to approve a reverse stock split to maintain its Nasdaq listing and a new equity incentive plan to attract and retain talent.

Brian and Barbara Pratt jointly report beneficial ownership of 1,085,934 shares, representing 12.5% of NeuroOne Medical Technologies Corporation's common stock.

Brian and Barbara Pratt have filed a Schedule 13G disclosing a 7.4% beneficial ownership stake in NeuroOne Medical Technologies Corporation.

Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 4.72% in NeuroOne Medical Technologies Corp as of September 30, 2025.

Bleichroeder LP and affiliates report a passive 8.03% beneficial ownership stake in NeuroOne Medical Technologies.

Sio Capital Management, LLC has disclosed a 7.07% beneficial ownership stake in NeuroOne Medical Technologies Corp, holding 3,523,663 common shares.

Laurence W. Lytton has filed an amended Schedule 13G, disclosing a 2.6% beneficial ownership stake in NeuroOne Medical Technologies Corp., held for passive investment purposes.